Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Pharm Res
2004 Jul 01;217:1303-10. doi: 10.1023/b:pham.0000033019.49737.28.
Show Gene links
Show Anatomy links
Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+).
Umapathy NS
,
Ganapathy V
,
Ganapathy ME
.
???displayArticle.abstract???
PURPOSE: The purpose of this study was to analyze the transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the Na(+)/Cl(-)-coupled amino acid transporter ATB(0,+).
METHODS: The interaction of amino acid esters and valganciclovir with the cloned rat ATB(0,+) was evaluated in a mammalian cell expression system and in the Xenopus oocyte expression system.
RESULTS: In mammalian cells, expression of ATB(0,+) induced glycine uptake. This uptake was inhibited by valine and its methyl, butyl, and benzyl esters. The benzyl esters of other neutral amino acids were also effective inhibitors. Valganciclovir, the valyl ester of ganciclovir, was also found to inhibit ATB(0,+)-mediated glycine uptake competitively. Exposure of ATB(0,+)-expressing oocytes to glycine induced inward currents. Exposure to different valyl esters (methyl, butyl, and benzyl), benzyl esters of various neutral amino acids, and valganciclovir also induced inward currents in these oocytes. The current induced by valganciclovir was saturable with a K0.5 value of 3.1+/-0.7 mM and was obligatorily dependent on Na+ and Cl-. The Na+:Cl-:valganciclovir stoichiometry was 2 or 3:1:1.
CONCLUSIONS: Amino acid esters and the amino-acid-based prodrug valganciclovir are transported by ATB(0,+). This shows that ATB(0,+) can serve as an effective delivery system for amino acid-based prodrugs.
???displayArticle.pubmedLink???
15290873
???displayArticle.link???Pharm Res ???displayArticle.grants???[+]
Anand,
Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.
2002, Pubmed
Anand,
Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.
2002,
Pubmed
Brown,
Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
1999,
Pubmed
Friedrichsen,
Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells.
2002,
Pubmed
Ganapathy,
Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.
1998,
Pubmed
Han,
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.
1998,
Pubmed
Hatanaka,
Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery.
2004,
Pubmed
,
Xenbase
Hatanaka,
Transport of D-serine via the amino acid transporter ATB(0,+) expressed in the colon.
2002,
Pubmed
,
Xenbase
Hatanaka,
Na+ - and Cl- -coupled active transport of nitric oxide synthase inhibitors via amino acid transport system B(0,+).
2001,
Pubmed
,
Xenbase
Nakanishi,
Na+- and Cl--coupled active transport of carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes.
2001,
Pubmed
,
Xenbase
Palacín,
Molecular biology of mammalian plasma membrane amino acid transporters.
1998,
Pubmed
Pescovitz,
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.
2000,
Pubmed
Sawada,
Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2.
1999,
Pubmed
Sloan,
Cloning and functional expression of a human Na(+) and Cl(-)-dependent neutral and cationic amino acid transporter B(0+).
1999,
Pubmed
,
Xenbase
Steingrimsdottir,
Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
2000,
Pubmed
Sugawara,
Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.
2000,
Pubmed
,
Xenbase
de Miranda,
Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
1994,
Pubmed
